News Detail

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Benzinga · 06/23 13:47

Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

HC Wainwright & Co. analyst Matthew Keller initiated coverage on Seres Therapeutics Inc (NASDAQ:MCRB) with a Buy rating and announced a price target of $12. Seres Therapeutics shares closed at $6.60 on Monday. See how other analysts view this stock.
HC Wainwright & Co. analyst Amit Dayal initiated coverage on XCF Global Inc (NASDAQ:SAFX) with a Buy rating and announced a price target of $1. XCF Global shares closed at $0.49 on Monday. See how other analysts view this stock.
Deutsche Bank analyst Kieran Ryan initiated coverage on DexCom Inc (NASDAQ:DXCM) with a Buy rating and announced a price target of $86. DexCom shares closed at $69.07 on Monday. See how other analysts view this stock.
Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation (NASDAQ:PODD) with a Buy rating and announced a price target of $190. Insulet shares closed at $138.97 on Monday. See how other analysts view this stock.
Deutsche Bank analyst Kieran Ryan initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:TNDM) with a Hold rating and announced a price target of $15.5. Tandem Diabetes Care shares closed at $14.34 on Monday. See how other analysts view this stock.

Considering buying MCRB stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.